Asthma phenotypes today

European Annals of Allergy and Clinical Immunology

Volumn 45, Issue 1, 2013, Pages 17-24

  Cottini, M ^a   Asero, R ^b  

^a Specialista in Allergologia e Immunologia Clinica   (Italy)

^b CLINICA SAN CARLO   (Italy)

Author keywords

Asthma; Bronchial hyperresponsiveness; Corticosterois; Eosinophils; Neutrophils; Therapy

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEBRIKIZUMAB; MEPOLIZUMAB; OMALIZUMAB;

AGE DISTRIBUTION; ALLERGIC ASTHMA; ASPIRIN EXACERBATED ASTHMA; ASTHMA; CORTICOSTEROID THERAPY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; ENDOTYPE; EOSINOPHILIC ASTHMA; GENETIC ANALYSIS; GENETIC PARAMETERS; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; MEDLINE; PATHOPHYSIOLOGY; PHENOTYPE; RESPIRATORY TRACT INFLAMMATION; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

AGE OF ONSET; ASTHMA; HUMANS; LUNG; PHENOTYPE; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84875401717     PISSN: 17641489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. The Encarta World Dictionary. New York: St Martin's Press; 1999.
2. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 2007; 120 (5 suppl): S94-S138.
3. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006; 368: 780-93.
4. Rackemann FM. A clinical classification of asthma. Am J Med Sci 1921; 12: 802-3.
5. Martinez F. Asthma and Wheezing in the first Six Years of Life. N Eng J Med 1995.
6. Borish L. Asthma: a syndrome composed of heterogeneus diseases. Ann Allergy Asthma Immunol 2008; 101: 1-9.
7. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet. 2006;368:804-813
8. Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophillic inflammation. J Allergy Clin Immunol 2004; 113: 101-8.
9. Bouzigon E, Corda E, Aschard H, et al. Effect of 17q21 variants and smoking exposure in early-onset asthma. N Eng J Med 6; 359 (19):1985-94.
10. Kuriakose JS, Miller RL. Environmental epigenetics and allergic diseases: recent advances. Clinical & Experimental Allergy, 2010.
11. ten Brinke A, Zwinderman AH, Sterk PJ, et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164: 744-8.
12. de Marco R, Marcon A, Jarvis D et al. Inhaled steroids are associated with reduced lung function decline in subjects with asthma with elevated total IgE. J Allergy Clin Immunol 2007; 119 (3): 611-7.
13. Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol 2011; 11 (6): 586-93.
14. Passalacqua G. Specific immunotherapy: beyond the clinical scores. Ann Allergy Asthma Immunol 2011; 107 (5): 401-6.
15. Global Strategy for Asthma Management and Prevention 2011 (update). www.ginasthma.org
16. Busse WW, Morgan WJ, Gergen PJ, et al. Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children. N Engl J Med 2011; 364: 1005-15.
17. Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34: 632-8.
18. Buhl R, Hanf G, Soler M et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002; 20: 1088-94.
19. Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clinical & Experimental Allergy 2009; 39: 788-97.
20. Bel EH. Clinical phenotypes of asthma. Curr Opin Pulm Med 2004; 10: 44-50.
21. Hizawa N, Yamaguchi E, Konno S, et al. A functional polymorphism in the RANTES gene promoter is associated with the development of late-onset asthma. Am J Respir Crit Care Med 2002; 166: 686-90.
22. Lee JH, Haselkorn T, Borish L et al. Risk factors associated with persistent airflow limitation in severe or difficult to-treat asthma: insights from the TENOR Study. Chest 2007; 132: 1882-9.
23. Kaminska M, Foley S, Maghni K et al. Airway remodeling in subjects with severe asthma with or without chronic persistent airflow obstruction. J Allergy Clin Immunol 2009; 124: 45-51.
24. ten Brinke A. Risk factors associated with irreversible airflow limitation in asthma. Curr Opin Allergy Clin Immunol 2008; 8 (1): 63-9.
25. Mascia K, Haselkorn T, Deniz YM et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005; 116: 970-5.
26. Simon RA. Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep 2004; 4: 17-24.
27. Fahrenholz JM. Natural history and clinical features of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol 2003; 24: 113-24.
28. Gaber F, Daham K, Higashi A. Increased levels of cysteinylleukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. Thorax 2008; 63: 1076-1082.
29. Dahlen SE, Malmstrom K, Nizankowska E, et al. Improvement of Aspirin-Intolerant Asthma by Montelukast, a Leukotriene Antagonist. Am J Respir Crit Care Med 2002; 165.
30. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111: 913-21.
31. Wardlaw AJ, Dunnette S, Gleich GJ, et al. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma: Relationship to bronchial hyperreactivity. Am Rev Respir Dis 1988; 137: 62-9.
32. Douwes J, Gibson P, Pekkanen J, Pearce N. Non-eosinophilic asthma: importance and possible mechanisms. Thorax 2002; 57: 643-8.
33. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160: 1001-8.
34. Green RH, Brightling CE, Bradding P. The reclassification of asthma based on subphenotypes. Curr Opin Allergy Clin Immunol 2007; 7: 43-50.
35. Bousquet J, Chanez P, et al. Eosinophillic inflammation in asthma. N Engl J Med 1990; 323: 1033-9.
36. Balkissoon RC, Balzar S, Rhodes D, et al. Eosinophils persist in the distal lung of severe asthma despite low numbers in proximal airways American Thoracic Society Annual Meeting, San Diego, CA, USA, 2006. A15.
37. Berry M, Hargadon B, Morgan A, et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Respir J 2005; 25: 986-91.
38. Louis R, Lau LC, Brown A, et al. The relationship between air-ways inflammation and asthma severity. Am J Respir Crit Care Med 2000; 161: 9-16.
39. Berry M, Morgan A, Shaw DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007; 62 (12): 1043-9.
40. Meijer RP, Postma DS, Kauffman HF, et al. Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. Clin Exp Allergy 2002; 32 (7): 1096-103.
41. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184 (5): 602-15.
42. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27: 483-94.
43. van Veen HP, ten Brinke A, Gauw SA, et al. Persistent sputum eosinophilia in patients with severe asthma: a 5-year follow-up study. American Thoracic Society Annual Meeting, San Diego, CA, USA 2005. A241
44. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360 (10): 973-84.
45. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360 (10): 985-93.
46. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180: 388-95.
47. Corren J, Lemanske RF Jr, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-98.
48. Simpson JL, Scott R, Boyle MJ et al. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006; 11: 54-61.
49. ibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophillic inflammation and increased sputum interleukin-8. Chest 2001; 119: 1329-36.
50. Douwes J, Gibson P, Pekkanen J, et al. Non-eosinophilic asthma: importance and possible mechanisms. Thorax 2002; 57: 643-8.
51. Drews AC, Pizzichini MM, Pizzichini E, et al. Neutrophilic air-way inflammation is a main feature of induced sputum in nonatopic asthmatic children. Allergy 2009; 64: 1597-601.
52. Green RH, Brightling CE, Woltmann G, et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57: 875-9.
53. Scott HA, Gibson PG, Garg ML et al. Airway inflammation is augmented by obesity and fatty acids in asthma. Eur Respir J 2011; 38 (3): 594-602.
54. Foschino-Barbaro MP, Costa VR, Resta O, et al. Menopausal asthma: a new biological phenotyphe? Allergy 2010.
55. Wenzel SE, Szefler SJ, Leung DYM, et al. Bronchoscopic evaluation of severe asthma: Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997; 156: 737-43.
56. Sur S, Crotty TB, Kephart GM, et al. Sudden-onset fatal asthma-a distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am Rev Respir Dis 1993; 148: 713-9.
57. James AL, Elliot JG, Abramson MJ, et al. Time to death, airway wall inflammation and remodelling in fatal asthma. Eur Respir J 2005; 26: 429-34.
58. Simpson JL, Grissell TV, Douwes J, et al. Innate immune activation in neutrophilic asthma. Thorax 2007; 62: 211-8.
59. Druilhe A, Letuve S, Pretolani M. Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action. Apoptosis 2003; 8: 481-95.
60. Cowan DC, Cowan JO, Palmay R et al. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 2010; 65: 384-90.
61. Jeffery PK, Venge P, Gizycki MJ et al. Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J 2002; 20: 1378-85.
62. Maneechotesuwan K, Essilfie-Quaye S, Meah S, et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest 2005; 128: 1936-42.
63. Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol 2007; 119: 1055-62.
64. Kerstjens HA, Disse B, Schroder-Babo W, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011; 128: 308-14.
65. Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010; 363: 1715-26.
66. Iwamoto H, Yokoyama A, Shiota N et al. Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur Respir J 2008; 31 (6): 1379-80.
67. Bousquet J, Aubier M, Sastre J, et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 2006; 61: 72-8.
68. Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010; 138: 1202-12.
69. Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008; 177: 148-55.
70. Tintinger GR, Feldman C, Theron AJ et al. Montelukast: more than a cysteinyl leukotriene receptor antagonist? ScientificWorld-Journal 2010; 10: 2403-13.
71. Gravett CM, Theron AJ, Steel HC et al. Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils. Eur Respir J 2010; 36 (6): 1417-24.
72. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354: 697-708.
73. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60: 1012-8.
74. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of TNF-a blockadein severe persistent asthma. Am J Respir Crit Care Med 2009; 179: 549-58.
75. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008; 372 (9643): 1107-19.
76. Lotvall J, Akdis CA, Bacharier LB et al., Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127: 355-60.
77. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes Clin Exp Allergy 2012 [Epub ahead of print].
78. Moore WC, Meyers D, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med 2010; 181: 315-23.
79. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178: 218-24.
80. Sutherland ER, Lehman EB, Teodorescu M et al. Body mass index and phenotype in subjects with mild-to-moderate persistent asthma. J Allergy Clin Immunol 2009; 123 (6): 1328-34.e1.
81. Stenius-Aarniala B, Poussa T, Kvarnström J, et al. Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. BMJ 2000; 320 (7238): 827-32.
82. Dixon AE, Pratley RE, Forgione PM et al Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J Allergy Clin Immunol 2011; 128 (3): 508-15.